JP2007513092A - Ｉｃｅ阻害剤を使用する感染性疾患の処置 - Google Patents

Ｉｃｅ阻害剤を使用する感染性疾患の処置 Download PDF

Info

Publication number
JP2007513092A
JP2007513092A JP2006541503A JP2006541503A JP2007513092A JP 2007513092 A JP2007513092 A JP 2007513092A JP 2006541503 A JP2006541503 A JP 2006541503A JP 2006541503 A JP2006541503 A JP 2006541503A JP 2007513092 A JP2007513092 A JP 2007513092A
Authority
JP
Japan
Prior art keywords
compound
ice
agents
infection
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006541503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513092A5 (https=
Inventor
ジョン シー． アール． ランドル，
ジョージ クー，
リンダ ハズレット，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2007513092A publication Critical patent/JP2007513092A/ja
Publication of JP2007513092A5 publication Critical patent/JP2007513092A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2006541503A 2003-12-01 2004-12-01 Ｉｃｅ阻害剤を使用する感染性疾患の処置 Pending JP2007513092A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52636203P 2003-12-01 2003-12-01
PCT/US2004/040345 WO2005053665A1 (en) 2003-12-01 2004-12-01 Treating infectious diseases using ice inhibitors

Publications (2)

Publication Number Publication Date
JP2007513092A true JP2007513092A (ja) 2007-05-24
JP2007513092A5 JP2007513092A5 (https=) 2008-01-24

Family

ID=34652445

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006541503A Pending JP2007513092A (ja) 2003-12-01 2004-12-01 Ｉｃｅ阻害剤を使用する感染性疾患の処置

Country Status (7)

Country Link
US (1) US20050233974A1 (https=)
EP (1) EP1696894A1 (https=)
JP (1) JP2007513092A (https=)
CN (2) CN101524351A (https=)
AU (1) AU2004294343A1 (https=)
CA (1) CA2547670A1 (https=)
WO (1) WO2005053665A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115362A1 (en) * 2004-05-15 2005-12-08 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
CA2567080A1 (en) * 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
CN101534824A (zh) * 2006-11-17 2009-09-16 艾博特公司 作为化学活素受体拮抗剂的氨基吡咯烷
WO2011094426A1 (en) 2010-01-29 2011-08-04 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Caspase inhibitors
EP4225301A1 (en) * 2020-10-07 2023-08-16 Institut National de la Santé et de la Recherche Médicale Treatments of coronavirus infections, cytokine release syndrome, cytokine storm syndrome, or diseases associated with excessive activation of inflammasomes by the use of inhibitors of inflammatory caspases
FR3114741A1 (fr) * 2020-10-07 2022-04-08 Etienne Jacotot Traitements des infections à coronavirus, du syndrome de libération de cytokine, du syndrome de la tempête de cytokines ou des maladies associées à l'activation excessive des inflammasomes par l'utilisation d'inhibiteurs des caspases inflammatoires.
CN116041418A (zh) * 2021-10-28 2023-05-02 苏州裕泰医药科技有限公司 羟脯氨酰基-丝氨酸化合物及其制备方法和应用
CN116041419B (zh) * 2021-10-28 2025-12-12 苏州裕泰医药科技有限公司 羟脯氨酰基-丝氨酸化合物及其制备和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
JP2002506878A (ja) * 1998-03-19 2002-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼのインヒビター
WO2002085899A1 (en) * 2001-04-19 2002-10-31 Vertex Pharmaceuticals Incorporated Heterocyclyldicarbamides as caspase inhibitors
JP2003534320A (ja) * 2000-05-19 2003-11-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｉｃｅ阻害剤のプロドラッグ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6201118B1 (en) * 1998-08-19 2001-03-13 Vertex Pharmaceuticals Inc. Process for forming an N-acylated, N,N-containing bicyclic ring from piperazic acid or an ester thereof especially useful as an intermediate in the manufacture of a caspase inhibitor
EP1542768A1 (en) * 2002-09-20 2005-06-22 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
TW200509958A (en) * 2003-02-14 2005-03-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
JP2002506878A (ja) * 1998-03-19 2002-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼのインヒビター
JP2003534320A (ja) * 2000-05-19 2003-11-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｉｃｅ阻害剤のプロドラッグ
WO2002085899A1 (en) * 2001-04-19 2002-10-31 Vertex Pharmaceuticals Incorporated Heterocyclyldicarbamides as caspase inhibitors

Also Published As

Publication number Publication date
WO2005053665A1 (en) 2005-06-16
EP1696894A1 (en) 2006-09-06
US20050233974A1 (en) 2005-10-20
CN1901892A (zh) 2007-01-24
AU2004294343A1 (en) 2005-06-16
CA2547670A1 (en) 2005-06-16
CN101524351A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
Robertson et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans
US20230285355A1 (en) Compounds for treating ophthalmic diseases and disorders
KR101951511B1 (ko) 레바미피드와 누액 유지 작용을 갖는 약제를 포함하는 전안부 질환 치료제
Proksch et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans
TWI535441B (zh) 用以避免或治療乾眼症之含瑞巴派特或其前藥之口服藥物組成
Romanowski et al. The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar®(gatifloxacin 0.3%) in a NZW rabbit model
TWI832920B (zh) 抑制軟性隱形眼鏡變質之眼科用組成物
JP2022546980A (ja) ブドウ膜炎の治療のための眼科用組成物
Thakur et al. Caspase-1 inhibitor reduces severity of Pseudomonas aeruginosa keratitis in mice
JP2022185062A (ja) 点眼剤
Burns et al. Inhibition of Pseudomonas aeruginosa elastase and Pseudomonas keratitis using a thiol-based peptide
JP2007513092A (ja) Ｉｃｅ阻害剤を使用する感染性疾患の処置
US20170239330A1 (en) Formulations for histatin therapeutics
Öztürk et al. Penetration of topical and oral ofloxacin into the aqueous and vitreous humor of inflamed rabbit eyes
Lee et al. A comparison of invasive and cytotoxic Pseudomonas aeruginosa strain-induced corneal disease responses to therapeutics
Pollack et al. Failure of intravitreal dexamethasone to diminish inflammation or retinal toxicity in an experimental model of Bacillus cereus endophthalmitis
WO2016196989A1 (en) Topical composition
HK1132656A (en) Treating infectious diseases using ice inhibitors
AKANDA et al. Efficacy of Perioperative Oral Antibiotics in the Prevention of Acute Infective Endophthalmitis after SICS
Jung et al. Ocular surface disease in patients with glaucoma
HK1099698A (en) Treating infectious diseases using ice inhibitors
US20260048096A1 (en) Methods and compositions for preserving the retinal outer nuclear layer (onl), photoreceptors, and retinal thickness
Dumitrache Ophthalmological Pathology and Management in Eye Diseases: Uvea
JP2016034936A (ja) 角膜上皮障害治療剤の組み合わせ
Koo et al. Corneal diseases in children: infectious keratitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110426